Abstract:Objective To evaluate the clinical efficacy and safety of iMliximab (IFX) in the treatment of Crohn's disease (CD).Methods From February 2009 to March 2013,the clinical data of 62 CD patients with IFX treatment were retrospectively analyzed.At week 14th after IFX injection and the end of follow-up of this study (March 2013) were two observation points.At week 14th after IFX injection (three times of IFX injection),C reactive protein (CRP) level,Crohn's disease activity index (CDAI) score and clinical remission were investigated.At the end of follow-up,clinical remission,fistula closure,mucosal healing and side effects were inspected.Normal distribution data were expressed as 2±s,which were compared with t test.Non normal distribution data were expressed as M (QL-QU) and compared with Wilcoxon test.Results Four cases without complete three times of IFX injection and one case lost to follow-up were eliminated.And nine postoperation cases with IFX treatment to prevent recurrence after surgery were excluded.A total of 48 cases of CD in active period were enrolled in this study on efficacy.At week 14th,CRP level of 48 patients [1.9(0.5,5.4) mg/L]decreased compared with that before treatment [28.9(6.4,51.1) mg/L] (Z=-5.468,P＜0.01);CDAI score (87.0±35.8) also decreased compared with that before treatment (245.1±59.1) (t=18.579,P＜0.01).At week 14th,46 patients in active period achieved clinical remission and the remission rate was 95.8％.By the end of follow-up,38 patients were still in remission period and the remission rate was 79.2％.Among 26 patients with anal fistula before IFX treatment,seven cases (26.9％) were completely closed,17 cases (65.4％) was partially closed and two cases was responseless.Fifteen patients were reviewed by colonoscopic examination after more than six times of IFX treatment.The median of simple endoscopic score for Crohn's disease (SES-CD) was 3 (0,5)after treatment,which decreased compared with that before treatment (8(7,9),Z=-3.306,P=0.001).Twenty-two of 48 cases in active period received,step-up strategy and 26 cases received with top-down strategy.At week 14th,20 cases (90.9％) of group with step-up strategy and 26 cases (100.0％) of group with top-down strategy were in remission period.By the end of follow-up,14 cases (63.6％) of group with step-up strategy and 24 cases (92.3％) of group with top down strategy maintained remission.Among 26 cases with anal fistula,two cases without response were treated with step-up strategy and seven cases with complete closure were all with top-down strategy.Among 62 patients,five had side effects,three of whom had acute infusion reaction,one had delayed infusion reaction and the other had anemia.Conclusions IFX had good clinical efficacy in controlling inflammation,inducing clinical remission,promoting fistula closure and mucosal healing in CD patients.For some CD patients with high risk,the initial top-down strategy showed good clinical efficacy.

P652 Compare Risk Factors Associated with Infectious Complication in Crohn’s Disease with and Without Preoperative Infliximab

Compare Risk Factors Associated with Postoperative Infectious Complication in Crohn’s Disease with and Without Preoperative Infliximab Therapy: a Cohort Study

The predictive factors for postoperative intra-abdominal septic complications after intestinal resection in patients with Crohn's Disease

Preoperative Infliximab Use and Postoperative Complications in Crohn's Disease: A Systematic Review and Meta-Analysis

Meta-Analysis: the Influence of Preoperative Infliximab Use on Postoperative Complications of Crohn’s Disease

Meta-Analysis: Pre-Operative Infliximab Treatment and Short-Term Post-Operative Complications in Patients with Ulcerative Colitis

Analysis of Adverse Effects of Infliximab Treatment in 486 Patients with Crohn′s Disease

Meta Analysis on Association Between Preoperative Infliximab Administration and Morbidity of Postoperative Infectious Complication in Patients with Ulcerative Colitis

Clinical efficacy of infliximab in the treatment of 62 cases with Crohn's disease

Meta‐analysis: Effect of Preoperative Infliximab Use on Early Postoperative Complications in Patients with Ulcerative Colitis Undergoing Abdominal Surgery

Rrisk factors, pathogenic bacteria and drug resistance of postoperative surgical site infection in patients with Crohn's disease

A Meta-Analysis of Efficacy and Safety of Infliximab for Prevention of Postoperative Recurrence in Patients with Crohn’s Disease

Postoperative Ratio of C-Reactive Protein to Albumin As a Predictive Marker in Patients with Crohn’s Disease Undergoing Bowel Resection

P-030 Infliximab and Tuberculosis Infection

P568 Does Infliximab Therapy Increase Incidence of Tuberculosis in Patients with Inflammatory Bowel Disease in an Endemic Area: a Nationwide Study from China

Risk of Tuberculosis During Infliximab Therapy for Inflammatory Bowel Disease, Rheumatoid Arthritis, and Spondyloarthropathy: A Meta-Analysis

P430 Long-term Outcome of Crohn's Disease Patients Treated with Infliximab

P1080 Real-world Study on Early Predictors of Infliximab Treatment Efficacy in Crohn's disease

Longer Diagnosis-surgery Duration Is Associated With an Increased Risk of Early Postoperative Complications for Crohn's Disease: A Retrospective Study

P907 Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn’s Disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysis

The Role of ABO Blood Groups in Crohn's Disease and in Monitoring Response to Infliximab Treatment.